Further studies with larger sample sizes are needed to validate the impact of sortilin on lipid and glucose metabolism in PCOS in order to be able to accurately assess its use as a potential therapeutic target for the management of the metabolic consequences of PCOS. The gene discussed is SORT1; the disease is polycystic ovary syndrome.